Roy Jakobs, CEO of Koninklijke Philips NV – (AMS:PHIA), has outlined the strategic direction for his company following a $1.1 billion settlement relating to defective sleep apnea products.
Philips’ settlement with US plaintiffs is expected to lift a significant burden from the legal system and enable it to focus more on growth and innovation.
Jakobs stated in an interview to CNBC that the financial agreement was not only a solution, but also a crucial step toward revitalizing Philips strategic direction.
Philips is preparing for a big deal
Philips reported stronger-than-expected earnings for the second quarter, a performance partly attributed to the resolution of the litigation issue.
Jakobs stated that investor confidence has been boosted by the agreement, as Philips’ shares have risen over 10% since the announcement.
Philips has a positive outlook for the future, as reflected by its financial performance and share price.
Philips is optimistic about the future of its business despite ongoing challenges including an investigation by the Department of Justice.
Jakobs reaffirmed the company’s expectations of a 5,0% increase in sales comparables for the entire year. This is due to a robust performance throughout its various business units.
It is expected that the company will be able to significantly increase its financial strength by 2024, as it has already finalized major deals both in North America and Europe.
Philips anticipates a recovery in China
Jakobs stressed the strategic significance of China by describing it as “a fundamentally attractive growth market”. Jakobs is still optimistic about the future of the Chinese market, despite the fact that the company experienced some weakness in the Chinese marketplace during the second-quarter.
Philips is a major player in China with a presence of nearly 100 years. It continues to invest in innovation in this region and capitalize on new opportunities.
Philips has seen a significant increase in its consumer business compared with healthcare. This is due to the different dynamics of each region.
Jakobs highlighted the new growth in markets like Indonesia and Middle East. Meanwhile, North America remains a stronghold of Philips Healthcare.
The geographical diversification of the economy is expected to boost future growth, and reduce regional volatility.
Philips is undergoing an extensive restructuring since 2022 to improve operational efficiency.
The restructuring plan includes a reduction of the workforce globally by 13% (equivalent to 10,000 jobs) and a cost-cutting measure of EUR195million ($211million).
Jakobs believes that these changes are essential to streamline operations and position the company for long-term sustained growth.
Wall Street analysts are predicting a fair price of $28.53 for Philips’ stock as it approaches its next quarterly earnings report.
Analysts think there’s potential for another 10% increase, showing confidence in both the strategic direction of the company and its recovery efforts.
Click here to read Koninklijke Philips NV’s full quarter release.
The post Philips CEO describes growth strategy following $1.1 billion settlement and aims to increase innovation, may change as new information becomes available.
This site is for entertainment only. Click here to read more
